← Scroll for more →
Fate Therapeutics Inc (FATE)
Biological Products, (No Diagnostic Substances)
Latest Price
$2.17
TTM P/E
--
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
1.32
P/B Ratio
1.65
Institutional Ownership
57.2% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12.87M | $34.0M | 11.03% | -- | 2026-06-30 |
| BlackRock, Inc. | 7.30M | $19.0M | 6.25% | -2.77M | 2026-06-30 |
| Vanguard Portfolio Management LLC | 4.55M | $12.0M | 3.90% | +411.3K | 2026-06-30 |
| Vanguard Capital Management LLC | 4.45M | $12.0M | 3.81% | +253.5K | 2026-06-30 |
| AQR Capital Management LLC | 3.84M | $10.0M | 3.29% | +835.7K | 2026-06-30 |
| Two Sigma Investments, LP | 3.59M | $9.0M | 3.08% | -- | 2026-06-30 |
| Johnson & Johnson | 3.38M | $9.0M | 2.90% | -- | 2026-06-30 |
| Renaissance Technologies LLC | 2.98M | $8.0M | 2.56% | +8.6K | 2026-06-30 |
| Millennium Management LLC | 2.43M | $6.0M | 2.09% | +1.91M | 2026-06-30 |
| Goldman Sachs Group Inc | 2.05M | $5.0M | 1.76% | +721.4K | 2026-06-30 |